Cargando…

Liposomal Doxorubicin in the Treatment of Breast Cancer Patients: A Review

Drug delivery systems can provide enhanced efficacy and/or reduced toxicity for anticancer agents. Liposome drug delivery systems are able to modify the pharmacokinetics and biodistribution of cytostatic agents, increasing the concentration of the drug released to neoplastic tissue and reducing the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lao, Juan, Madani, Julia, Puértolas, Teresa, Álvarez, María, Hernández, Alba, Pazo-Cid, Roberto, Artal, Ángel, Antón Torres, Antonio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2013
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3619536/ https://www.ncbi.nlm.nih.gov/pubmed/23634302 http://dx.doi.org/10.1155/2013/456409

Ejemplares similares

Substituting Doxorubicin with Nonpegylated Liposomal Doxorubicin for the Treatment of Early Breast Cancer: Results of a Retrospective Study
por: Davidson, Neville, et al.
Publicado: (2014)

Anticancer and cardio-protective effects of liposomal doxorubicin in the treatment of breast cancer
por: Franco, Yesenia L, et al.
Publicado: (2018)

Comparative effects of free doxorubicin, liposome encapsulated doxorubicin and liposome co-encapsulated alendronate and doxorubicin (PLAD) on the tumor immunologic milieu in a mouse fibrosarcoma model
por: Islam, Md. Rakibul, et al.
Publicado: (2022)

Clinical Trials with Pegylated Liposomal Doxorubicin in the Treatment of Ovarian Cancer
por: Pisano, Carmela, et al.
Publicado: (2013)

Cardiac Safety of Pegylated Liposomal Doxorubicin After Conventional Doxorubicin Exposure in Patients With Sarcoma and Breast Cancer
por: Alhaja, Maher, et al.
Publicado: (2023)

Pharmacokinetics and Efficacy of PEGylated Liposomal Doxorubicin in an Intracranial Model of Breast Cancer
por: Anders, Carey K., et al.
Publicado: (2013)

Pegylated liposomal doxorubicin in ovarian cancer
por: Green, Andrew E, et al.
Publicado: (2006)

Pegylated liposomal doxorubicin in ovarian cancer
por: Strother, Robert, et al.
Publicado: (2009)

Pegylated liposomal doxorubicin for myeloid neoplasms
por: Zhang, Cheng, et al.
Publicado: (2019)

Reversal of Multidrug Resistance by Apolipoprotein A1-Modified Doxorubicin Liposome for Breast Cancer Treatment
por: An, Duopeng, et al.
Publicado: (2021)

Pegylated liposomal doxorubicin in the treatment of AIDS-related Kaposi’s sarcoma
por: Udhrain, Ashish, et al.
Publicado: (2007)

A multicentric observational trial of pegylated liposomal doxorubicin for metastatic breast cancer
por: Huober, Jens, et al.
Publicado: (2010)

Gemcitabine and doxorubicin in immunostimulatory monophosphoryl lipid A liposomes for treating breast cancer
por: Wu, Debra, et al.
Publicado: (2020)

Dual-Functional Peptide Driven Liposome Codelivery System for Efficient Treatment of Doxorubicin-Resistant Breast Cancer
por: Ahmed, Kamel S, et al.
Publicado: (2021)

Pegylated liposomal doxorubicin in the management of ovarian cancer
por: Ferrandina, Gabriella, et al.
Publicado: (2010)

A tale of the two PEGylated liposomal doxorubicins
por: Chou, Hunghsueh, et al.
Publicado: (2015)

Liposomal doxorubicin-induced palmoplantar erythrodysthesia syndrome
por: Yadav, Nidhi, et al.
Publicado: (2015)

Analytical ultracentrifugation for analysis of doxorubicin loaded liposomes
por: Mehn, Dora, et al.
Publicado: (2017)

Pharmacokinetics of a liposomal formulation of doxorubicin in rats
por: Liu, Zongyu, et al.
Publicado: (2017)

Recent Preclinical and Clinical Progress in Liposomal Doxorubicin
por: Aloss, Kenan, et al.
Publicado: (2023)

Immunotoxicity of multiple dosing regimens of free doxorubicin and doxorubicin entrapped in cardiolipin liposomes.
por: Rahman, A., et al.
Publicado: (1986)

Non-Pegylated Liposomal Doxorubicin-Cyclophosphamide in Sequential Regimens with Taxanes as Neoadjuvant Chemotherapy in Breast Cancer Patients
por: Vici, Patrizia, et al.
Publicado: (2014)

A Case of Metaplastic Breast Cancer with Prolonged Response to Single Agent Liposomal Doxorubicin
por: Hamad, Lamya, et al.
Publicado: (2016)

Single-agent pegylated liposomal doxorubicin (PLD) in the treatment of metastatic breast cancer: results of an Austrian observational trial
por: Fiegl, Michael, et al.
Publicado: (2011)

Pharmaceutical and Biomedical Differences between Micellar Doxorubicin (NK911) and Liposomal Doxorubicin (Doxil)
por: Tsukioka, Yoshihisa, et al.
Publicado: (2002)

Development and Characterization of Liposomal Doxorubicin Hydrochloride with Palm Oil
por: Sabeti, Bahareh, et al.
Publicado: (2014)

Lactosylated liposomes for targeted delivery of doxorubicin to hepatocellular carcinoma
por: Zhou, Xiaoju, et al.
Publicado: (2012)

Ehrlich tumor inhibition using doxorubicin containing liposomes
por: Elbialy, Nihal Saad, et al.
Publicado: (2015)

Pegylated Liposomal Doxorubicin-induced Palmar-plantar Erythrodysesthesia
por: Moreira-Barros, Joana, et al.
Publicado: (2018)

Prolonged use of pegylated liposomal doxorubicin in gynecologic malignancies
por: Yost, S., et al.
Publicado: (2019)

Pegylated liposomal doxorubicin in patients with epithelial ovarian cancer
por: Yuan, Zhen, et al.
Publicado: (2021)

Impact of PEGylated Liposomal Doxorubicin and Carboplatin Combination on Glioblastoma
por: Ghaferi, Mohsen, et al.
Publicado: (2022)

Phase II study of liposomal doxorubicin and gemcitabine in the salvage treatment of ovarian cancer
por: D'Agostino, G, et al.
Publicado: (2003)

Liposome-Fe(3) O(4)-Doxorubicin Mediated Treatment of Melanoma Tumors
por: Azlegini, Azalia, et al.
Publicado: (2023)

Pegylated Liposomal Doxorubicin Versus Epirubicin as Adjuvant Therapy for Stage I–III Breast Cancer
por: Hu, Wenxian, et al.
Publicado: (2021)

Biomarkers of PEGylated Liposomal Doxorubicin-Induced Hypersensitivity Reaction in Breast Cancer Patients Based on Metabolomics
por: Zhuang, Wei, et al.
Publicado: (2022)

ROS-responsive liposomes with NIR light-triggered doxorubicin release for combinatorial therapy of breast cancer
por: Yi, Hanxi, et al.
Publicado: (2021)

Irinotecan Plus Doxorubicin Hydrochloride Liposomes for Relapsed or Refractory Wilms Tumor
por: Wang, Juan, et al.
Publicado: (2021)

Randomized phase II study of the PDGFRα antibody olaratumab plus liposomal doxorubicin versus liposomal doxorubicin alone in patients with platinum-refractory or platinum-resistant advanced ovarian cancer
por: McGuire, William P., et al.
Publicado: (2018)

Outcomes of AIDS-associated Kaposi sarcoma in Mozambique after treatment with pegylated liposomal doxorubicin
por: Coldiron, Matthew E., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_4jgdudl8tagl469fcpmp1vtdt4